0001104659-22-084972.txt : 20220802 0001104659-22-084972.hdr.sgml : 20220802 20220802074750 ACCESSION NUMBER: 0001104659-22-084972 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220802 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220802 DATE AS OF CHANGE: 20220802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 221126908 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 tm2222337d1_8k.htm FORM 8-K
0001597264 false 0001597264 2022-08-02 2022-08-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 2, 2022

 

 

 

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37359   26-3632015

(State or other jurisdiction

of incorporation)

   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

45 Sidney Street

Cambridge, Massachusetts

   02139
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 374-7580

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share BPMC Nasdaq Global Select Market

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 2, 2022, Blueprint Medicines Corporation announced its financial results for the quarter ended June 30, 2022 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

 

  Exhibit No.  Description 
  99.1 Press release issued by Blueprint Medicines Corporation on August 2, 2022
  104  Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BLUEPRINT MEDICINES CORPORATION
   
Date: August 2, 2022 By: /s/ Kathryn Haviland
    Kathryn Haviland
    Chief Executive Officer

 

 

 EX-99.1 2 tm2222337d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Blueprint Medicines Reports Second Quarter 2022 Results

 

-- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 –

 

-- Plan to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in August 2022 --

 

-- Licensed KIT exon 13 inhibitor to IDRx in exchange for a 15 percent Series A preferred equity investment, and the potential to receive up to $217.5 million in development, regulatory, and sales-based milestones and tiered percentage royalties --

 

-- Investor Day planned for November 1, 2022 in New York, NY --

 

CAMBRIDGE, Mass., August 2, 2022 – Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2022.

 

“We are now one year into the AYVAKIT launch in advanced systemic mastocytosis (SM) and continue to see a significant expansion of our prescriber base as well as strong patient demand, reinforcing our conviction in the growth opportunity in SM. ” said Kate Haviland, Chief Executive Officer of Blueprint Medicines. “We are on track to announce topline data from our registration-enabling PIONEER trial in August, which will catalyze our ability to bring AYVAKIT’s transformative potential to patients living with non-advanced SM. In addition, we continue to make significant progress across our pipeline of innovative investigational medicines in EGFR-mutant and CDK2-vulnerable cancers. We look forward to sharing more about our strategic vision, including the opportunities we see in SM, EGFR-mutant lung cancer, and CDK2-vulnerable cancers, and how our expanding research platform will continue to drive innovation at an Investor Day on November 1, 2022 in New York, NY. With our strong revenue performance, a clinical-stage pipeline of five significant assets, and well over $1 billion in cash on our balance sheet as of today, we are uniquely positioned to drive near- and long-term value for all of our stakeholders by delivering transformative precision medicines to patients around the world.”

 

Second Quarter 2022 Highlights and Recent Progress

 

AYVAKIT®/AYVAKYT® (avapritinib): systemic mastocytosis (SM) and PDGFRA gastrointestinal stromal tumor (GIST)

 

•Reported global net product revenues of $28.5 million for the second quarter of 2022.
•Presented new retrospective analyses at the European Hematology Association (EHA) 2022 Congress, showing that AYVAKIT significantly improved overall survival in patients with advanced SM when compared to real-world data for prior best available therapies, including midostaurin and cladribine. Read the press release here.
•Upon request by the FDA, changed the primary endpoint for the registrational PIONEER Part 2 trial of AYVAKIT in patients with non-advanced SM to the mean change in total symptom score (TSS).

 

GAVRETO® (pralsetinib): RET-altered cancers

 

•As previously recorded and reported by Roche, GAVRETO global product sales were 7 million CHF, which excludes sales in the Greater China territory driven by CStone Pharmaceuticals.
•Received approval in Hong Kong, China, via the collaboration with CStone Pharmaceuticals, for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC).

 

 

Corporate

 

•Announced strategic financing collaborations with Sixth Street and Royalty Pharma plc (Royalty Pharma) (NASDAQ: RPRX) for up to $1.25 billion, of which $175 million was funded as of June 30, 2022, and an additional $400 million funded in July 2022. Read the press release here.
•Licensed a development candidate-stage KIT exon 13 inhibitor, and licensed the compound to IDRx, Inc., a recently launched clinical-stage biopharmaceutical company, in exchange for a 15 percent Series A preferred equity investment and up to $217.5 million in future milestone payments and tiered percentage royalty payments.
•Published an inaugural Corporate Responsibility Report, highlighting the company’s long-standing commitment to delivering sustainable value to patients with cancer and blood disorders, as well as the communities in which Blueprint Medicines operates. Read the press release here and access the report here.
•Announced the appointment of Habib Dable, former Chief Executive Officer of Acceleron Pharma, Inc., to the company’s Board of Directors. Read the press release here.

 

Key Upcoming Milestones

 

The company plans to achieve the following near-term milestones:

 

•Present topline data from the registrational PIONEER Part 2 trial for avapritinib in non-advanced SM in August 2022 and submit a supplemental new drug application to the FDA for AYVAKIT in non-advanced SM in the second half of 2022.
•Share the strategic vision for Blueprint, including opportunities in SM, EGFR-mutant lung cancer, and CDK2-vulnerable cancers, and how our expanding research platform has the potential to deliver the promise of precision medicine to more patients at an Investor Day on November 1, 2022 in New York, NY.
•Present updated BLU-945 monotherapy data and initial dose escalation data for BLU-945 in combination with osimertinib from the Phase 1/2 SYMPHONY trial in EGFR-mutant NSCLC in the second half of 2022.
•Present initial clinical data from the Phase 1/2 HARMONY trial of BLU-701 in EGFR-mutant NSCLC in the second half of 2022.
•Present initial data from the HARBOR trial of BLU-263 in non-advanced SM in the second half of 2022.
•Present initial clinical data from the Phase 1/2 CONCERTO trial of BLU-451 in EGFR-mutant NSCLC in the first half of 2023.
•Present initial clinical data from the Phase 1/2 VELA trial of BLU-222 in CDK2-vulnerable cancers in the first half of 2023.

 

Second Quarter 2022 Results

 

•Revenues: Revenues were $36.5 million for the second quarter of 2022, including $28.5 million of net product revenues from sales of AYVAKIT/AYVAKYT and $8.0 million in collaboration revenues. Blueprint Medicines recorded revenues of $27.3 million in the second quarter of 2021, including $8.5 million of net product revenues from sales of AYVAKIT/AYVAKIT, $2.9 million of net product revenues from sales of GAVRETO and $15.9 million in collaboration revenues.
•Cost of Sales: Cost of sales was $4.9 million for the second quarter of 2022, as compared to $6.5 million for the second quarter of 2021.
•R&D Expenses: Research and development expenses were $128.5 million for the second quarter of 2022, as compared to $80.0 million for the second quarter of 2021. This increase was primarily due to increased costs associated with the progression of our clinical trials and increased costs related to early discovery effort. Research and development expenses included $10.5 million in stock-based compensation expenses for the second quarter of 2022.
•SG&A Expenses: Selling, general and administrative expenses were $58.7 million for the second quarter of 2022, as compared to $49.3 million for the second quarter of 2021. This increase was primarily due to increased costs associated with expanding our commercial infrastructure for commercialization of AYVAKIT/AYVAKYT. General and administrative expenses included $14.9 million in stock-based compensation expenses for the second quarter of 2022.
•Net Loss: Net loss was $159.7 million for the second quarter of 2022, or a net loss per share of $2.68, as compared to a net loss of $108.4 million for the second quarter of 2021, or a net loss per share of $1.86.
•Cash Position: As of June 30, 2022, cash, cash equivalents and investments were $947.2 million, as compared to $1,034.6 million as of December 31, 2021. Cash as of June 30, 2022, does not include $400 million gross proceeds received from our strategic non-dilutive financing agreements with Sixth Street, which closed and was funded in July 2022.

 

 

Financial Guidance

 

Blueprint Medicines anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AYVAKIT net product revenues. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.

 

Conference Call Information

 

Blueprint Medicines will host a live conference call and webcast at 8:00 a.m. ET today to discuss second quarter 2022 financial results and recent business activities. The conference call may be accessed by dialing 844-200-6205 (domestic) or 929-526-1599 (international), and referring to conference ID 694684. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

 

About Blueprint Medicines

 

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for interactions with the FDA and other regulatory authorities; plans and timelines to update the primary endpoint of the registrational PIONEER trial of AYVAKIT in patients with non-advanced SM; expectations regarding the potential benefits of AYVAKIT in treating patients with non-advanced SM; and the potential benefits of Blueprint Medicines' collaborations; and Blueprint Medicines' financial performance, strategy, goals and anticipated milestones, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines’ business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines’ ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines’ ability and plans in continuing to establish and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines’ ability to successfully expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines’ current or future drug candidates; Blueprint Medicines’ advancement of multiple early-stage efforts; Blueprint Medicines’ ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines’ drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it is developing; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines' ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines' ability to realize the anticipated benefits of its executive leadership transition plan; and the success of Blueprint Medicines’ current and future collaborations, financing arrangements, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines’ filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines’ most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

 

 

Trademarks

 

Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.

 

Blueprint Medicines Corporation

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

 

   June 30,   December 31, 
   2022   2021 
Cash, cash equivalents and investments  $947,159   $1,034,643 
Working capital (1)   793,419    404,260 
Total assets   1,192,446    1,252,225 
Deferred revenue (2)   22,139    36,576 
Liability related to the sale of future royalties (2)   171,254    - 
Total liabilities   444,696    281,490 
Total stockholders’ equity   747,750    970,735 

 

(1) Blueprint defines working capital as current assets less current liabilities.

 

(2) Includes both current and long-term portions of the balance

 

 

Blueprint Medicines Corporation

Condensed Consolidated Statements of Operations Data

(in thousands, except per share data)

(unaudited)

 

   Three Months Ended,
June 30		   Six Months Ended,
June 30		 
   2022   2021   2022   2021 
Revenues:                    
Product revenue, net  $28,454   $11,433   $52,295   $20,388 
Collaboration revenue   8,093    15,862    46,983    28,483 
Total revenues   36,547    27,295    99,278    48,871 
Cost and operating expenses:                    
Cost of sales   4,886    6,493    9,964    6,595 
Collaboration loss sharing   2,145    ----    5,410    ---- 
Research and development   128,466    80,027    231,599    159,738 
Selling, general and administrative   58,688    49,286    115,747    91,288 
Total cost and operating expenses  $194,185    135,806    362,720    257,621 
Other income (expense):                    
Interest income (expense), net   427    633    869    1,371 
Other income (expense), net   632    (373)   177    (587)
Total other income (expense)  $1,059    260    1,046    784 
Loss before income taxes  $(156,579)   (108,251)   (262,396)   (207,966)
Income tax expense   (3,130)   (193)   (3,313)   (193)
Net loss  $(159,709)  $(108,444)  $(265,709)  $(208,159)
Net loss per share — basic and diluted  $(2.68)  $(1.86)  $(4.47)  $(3.58)
Weighted-average number of common shares used in net loss per share — basic and diluted   59,617    58,406    59,465    58,216 

 

Media Contact

Sarah Mena Guerrero

617-714-6684

media@blueprintmedicines.com

 

Investor Contact

Jenna Cohen

857-209-3147

ir@blueprintmedicines.com

 

 

 EX-101.SCH 3 bpmc-20220802.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bpmc-20220802_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bpmc-20220802_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 02, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 02, 2022
Entity File Number 001-37359
Entity Registrant Name Blueprint Medicines Corporation
Entity Central Index Key 0001597264
Entity Tax Identification Number 26-3632015
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 45 Sidney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 374-7580
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BPMC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm2222337d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001597264 2022-08-02 2022-08-02 iso4217:USD shares iso4217:USD shares 0001597264 false 8-K 2022-08-02 Blueprint Medicines Corporation DE 001-37359 26-3632015 45 Sidney Street Cambridge MA 02139 617 374-7580 false false false false false Common stock, par value $0.001 per share BPMC NASDAQ EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://blueprintmedicines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2222337d1_8k.htm bpmc-20220802.xsd bpmc-20220802_lab.xml bpmc-20220802_pre.xml tm2222337d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2222337d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2222337d1_8k.htm" ] }, "labelLink": { "local": [ "bpmc-20220802_lab.xml" ] }, "presentationLink": { "local": [ "bpmc-20220802_pre.xml" ] }, "schema": { "local": [ "bpmc-20220802.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "BPMC", "nsuri": "http://blueprintmedicines.com/20220802", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222337d1_8k.htm", "contextRef": "From2022-08-02to2022-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://blueprintmedicines.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222337d1_8k.htm", "contextRef": "From2022-08-02to2022-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-084972-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-084972-xbrl.zip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end